Biomarkers to Predict CRT Response in Patients With HF (BIOCRT)
NCT ID: NCT01949246
Last Updated: 2022-10-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
221 participants
OBSERVATIONAL
2007-09-30
2016-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. To determine the role and mechanism of biomarkers for prediction of response to CRT
2. To determine the role of biomarkers and their effect on left ventricular remodeling in patients undergoing CRT.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Prevention of Myocardial Enlargement and Dilatation Post Myocardial Infarction Study
NCT00605631
One Day Implantation Program for Heart Failure Patients Implanted With CRT-P
NCT05142293
Circulating Biomarkers and Ventricular Tachyarrhythmia
NCT01892462
Application of Right Atrial Left Ventricular Fusion Pacing in Patients With CRT Indications
NCT03071978
Predicting Response to Cardiac Resynchronization Therapy in Heart Failure
NCT00359372
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Currently, the indications for CRT include end-stage heart failure class II-IV with an EF \< 35%, and a QRS duration \> 120ms. The QRS duration is used as an indicator of the degree of ventricular electromechanical dyssynchrony, however, a growing number of studies have postulated its inability to predict response to therapy. As a result, other measures of mechanical dyssynchrony are being sought to guide therapy. The vast majority of these studies have examined clinical, cardiac, electrocardiographic, and device-specific indices, however, a widely accepted predictor of response to CRT is lacking.
CRT results in electromechanical synchrony, leading to an improved ejection fraction, exercise tolerance, and reduction of symptoms. Although electrical re-synchronization and intra-procedural hemodynamic improvement are achieved after the device is implanted, the sustained clinical improvement is likely due to ventricular reverse remodeling. A major issue with CRT is that approximately a third of patients receiving devices do not achieve improved clinical or functional status, and fail to undergo changes in ventricular geometry, and ventricular remodeling. It remains unknown whether this is due to abnormalities in the factors involved in lead placement or procedural strategies, geometric remodeling, alterations in cardiac energy metabolism, supply of energy (i.e. coronary blood flow), or inappropriate/inadequate microvascular proliferation.
This study will evaluate a series of biochemical markers implicated in pathophysiology of heart failure, in predicting response to CRT with biventricular pacing.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CRT patients
Patients undergoing CRT device implantation
No interventions assigned to this group
Healthy patients
Healthy controls
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. New York Heart Association (NYHA) Class II, III, or IV Heart Failure unresponsive to drug therapy.
2. EF \< 35%.
3. QRS width \> 120 ms.
* Study participant receiving optimal medical therapy including ACE inhibitor or Angiotensin Receptor Blocker (ARB), Beta-Blocker, and Diuretic.
* Study participants with a history of significant congestive decompensation events within the last 12 months.
Exclusion Criteria
* Co morbidities (e.g., cancer), which may limit lifespan \< 6 months.
* Severe aortic stenosis (valve area \< 1.0 cm2).
* Study participants that received cardiac surgery or intervention (i.e. coronary artery bypass grafting (CABG), valve surgery, angioplasty, arthrectomy) within the preceding 90 days.
* Study participants with moderate to severe chronic obstructive pulmonary disease (COPD), defined as needing chronic oxygen therapy or recent hospitalization (within 30 days) for COPD flare up.
* Concurrent pregnancy.
* Study participants with primary pulmonary hypertension.
* Study participants on continuous or intermittent infusion therapy for heart failure.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Massachusetts General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jagmeet Singh
Jagmeet P Singh, M.D. Ph.D.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jagmeet P Singh
Role: PRINCIPAL_INVESTIGATOR
Massachussetts General Hospital
Quynh A Truong, MD MPH
Role: PRINCIPAL_INVESTIGATOR
Weill Medical College of Cornell University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Massachusetts General Hospital
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Truong QA, Januzzi JL, Szymonifka J, Thai WE, Wai B, Lavender Z, Sharma U, Sandoval RM, Grunau ZS, Basnet S, Babatunde A, Ajijola OA, Min JK, Singh JP. Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: the BIOCRT study. Heart Rhythm. 2014 Dec;11(12):2167-75. doi: 10.1016/j.hrthm.2014.07.007. Epub 2014 Jul 8.
Ajijola OA, Chatterjee NA, Gonzales MJ, Gornbein J, Liu K, Li D, Paterson DJ, Shivkumar K, Singh JP, Herring N. Coronary Sinus Neuropeptide Y Levels and Adverse Outcomes in Patients With Stable Chronic Heart Failure. JAMA Cardiol. 2020 Mar 1;5(3):318-325. doi: 10.1001/jamacardio.2019.4717.
Bakos Z, Chatterjee NC, Reitan C, Singh JP, Borgquist R. Prediction of clinical outcome in patients treated with cardiac resynchronization therapy - the role of NT-ProBNP and a combined response score. BMC Cardiovasc Disord. 2018 Apr 24;18(1):70. doi: 10.1186/s12872-018-0802-8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2007P001921
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.